2020
Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives
Jamwal S, Elsworth JD, Rahi V, Kumar P. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives. Expert Review Of Neurotherapeutics 2020, 20: 1123-1141. PMID: 32720531, DOI: 10.1080/14737175.2020.1801424.Peer-Reviewed Original ResearchConceptsGene therapyClinical trialsDisease-modifying therapiesMutant huntingtinTreatment of HDAntibody-based therapiesPotential therapeutic interventionsNew therapeutic targetsGene-based therapiesImmune activationClinical dataImmunotherapyTherapeutic targetFunctional restorationTherapeutic interventionsTherapyHD pathogenesisMHTT proteinRecent updatesFuture perspectivesPromising strategyTrialsCurrent statusConsiderable attentionHD
2015
Animal models in regenerative medicine
Bubak A, Elsworth J, Sladek J. Animal models in regenerative medicine. 2015, 301-316. DOI: 10.1002/9781118846193.ch16.Peer-Reviewed Original ResearchAnimal modelsCurrent clinical therapeuticsClinical trialsStem cellsRegenerative medicineFuture clinical trialsAppropriate animal modelsHuman therapeuticsStem cell trialsCell trialsHuman studiesClinical settingClinical therapeuticsTranslational researchUnsuccessful trialsTrialsDiseaseSpecific diseasesChallenging goalOptimal techniqueTherapeuticsCellsLoss of confidence
1983
Panic-Induced Elevation of Plasma MHPG Levels in Phobic-Anxious Patients: Effects of Clonidine and Imipramine
Ko G, Elsworth J, Roth R, Rifkin B, Leigh H, Redmond D. Panic-Induced Elevation of Plasma MHPG Levels in Phobic-Anxious Patients: Effects of Clonidine and Imipramine. JAMA Psychiatry 1983, 40: 425-430. PMID: 6838322, DOI: 10.1001/archpsyc.1983.01790040079011.Peer-Reviewed Original ResearchConceptsPlasma MHPG levelsMHPG levelsEffects of clonidineSignificant symptom reductionPlasma MHPG concentrationSelf-rated anxietyPlacebo treatmentCrossover trialMHPG concentrationsPlasma levelsNoradrenergic activityDrug treatmentDrug trialsSymptom reductionDiminished suppressionPanic attacksPanic symptomsImipramine hydrochlorideClonidinePatientsPhobic stimuliImipramineTrialsAnxietyTreatment
1982
The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties
Elsworth J, Sandler M, Lees A, Ward C, Stern G. The contribution of amphetamine metabolites of (−)-deprenyl to its antiparkinsonian properties. Journal Of Neural Transmission 1982, 54: 105-110. PMID: 6809891, DOI: 10.1007/bf01249283.Peer-Reviewed Original Research